ERBB2 and breast carcinoma: Indeed, HER2-low expressing breast cancer is emerging as a novel distinct entity, possibly challenging the current diagnostic-therapeutic paradigm, shifting from a 2-tier to a 3-tier algorithm, encompassing HER2-“truly”-negative, HER2-positive and HER2-low tumors.